ARTICLE - Lanreotide Improves PFS in Pancreatic NET - TopicsExpress



          

ARTICLE - Lanreotide Improves PFS in Pancreatic NET Subgroup Lanreotide (Somatuline Depot) improved progression-free survival and resulted in more disease control compared with an observation strategy among patients with pancreatic neuroendocrine tumors (pNETs) in a planned subgroup analysis of the CLARINET trial, which led to the FDA’s recent approval of the agent. On December 16, 2014, the FDA approved lanreotide to improve progression-free survival in patients with unresectable, well- or moderately differentiated, locally advanced or metastatic GEP-NETs. Link below for full article.
Posted on: Fri, 23 Jan 2015 21:21:09 +0000

Trending Topics



Recently Viewed Topics




© 2015